g888 gun
Canada's financial intelligence agency aiming to provide crucial info in real timeLumber mill levelled by mid-morning blazeMinerva Neurosciences stock hits 52-week low at $2.07
Los Angeles Lakers Reportedly Interested In Veteran Forward
The Cincinnati Bearcats men's basketball team has gotten off to a fast start this season in more ways than one. The No. 16 Bearcats have raced to a 5-0 record while outscoring their opponents by more than 31 points per game, with just one team (Northern Kentucky) coming within 16 points. Cincinnati is averaging a robust 87 points per game with one of the more efficient offenses in college basketball. Cincinnati will look to continue that hot streak when it plays host to Alabama State in nonconference action Wednesday evening. Cincinnati has punished opposing defenses in a variety of ways this season. Despite being the No. 14 offense in the nation in Ken Pomeroy's efficiency ratings, the Bearcats aren't among the nation's leaders in pace. Still, they take advantage of those opportunities when they are there. "Us playing fast is something we want to do," Cincinnati forward Dillon Mitchell said. "When I was being recruited here, that was something Coach (Wes) Miller wanted to do. "There could be games where we're not making shots or something is off, but one thing is we're gonna push the ball, play hard and play fast. That's something he preaches. We'll be in shape and get rebounds." Mitchell is fresh off a double-double with 14 points and 11 rebounds in Cincinnati's 81-58 road win at Georgia Tech Saturday. He is one of four Bearcats to average double figures in scoring this season. That balance was on display once again against the Yellow Jackets, with Connor Hickman and Jizzle James also scoring 14 points each and Simas Lukosius contributing 12 points. In that game, Cincinnati sank 51.6 percent of its shots while regularly getting out into transition with 16 fastbreak points, while winning the rebounding battle 36-29. "Any time you get a road win over a quality, Power 4 team, you're gonna feel good about it," Miller said. "I was pleased with our effort." Lukosius is scoring 16.6 points per game, while James is at 14.0 points, followed by Mitchell at 12.4, while he also grabs a team-best 8.6 rebounds. Alabama State (3-3) has a tough task ahead, especially when considering its 97-78 loss at Akron Sunday, which ended a three-game winning streak. The Hornets allowed the Zips to shoot 46.4 percent from the field and were 53-32 in the rebounding battle. Alabama State gave up a season high in points, after playing the likes of LSU and UNLV earlier this season. Akron standout Nate Johnson lit up Alabama State for 25 points, as the game got away from the Hornets in the second half to keep them winless in true road games. Alabama leading scorers CJ Hines and TJ Madlock still got theirs against Akron, scoring 19 and 17 points, respectively. They were joined in double figures by reserve Tyler Mack (18 points), but recent history says they'll need more help to keep up with the Bearcats. Hines leads the Hornets with 15.7 points per game, while Madlock contributes 14.5 points. In previous Akron Basketball Classic wins last week against Omaha and Lamar, Alabama State featured at least four double-digit scorers in each game. --Field Level MediaPennsylvania State Police said remains found 51 years ago in a wooded area of Lebanon County have been identified as 14-year-old Ruth Brenneman, of York County, who disappeared after going to school one day. Two game wardens found her body under a tarp and brush on Oct. 10, 1973. The area where the decomposed body was found — near Fort Indiantown Gap — is about 47 miles from where she lived. Lebanon and York counties are located outside of Harrisburg, Pennsylvania. "Ruth was last seen in the beginning of the 1973 school year after she left for school and never returned home. Ruth Brenneman was a young female just shy of her 15 th birthday and known for her long blonde hair. We continue to investigate the circumstances around Ruth Brenneman’s discovery," Sgt. John Lacey said at a Thursday afternoon news conference. Police did not say how she died or whether her death was a homicide. Investigators said the key to identifying Brenneman was genealogy technology that was gathered using her DNA. Brenneman’s family prepared a statement, which Lacey read at the news conference: "The family wishes to extend our gratitude to Trooper Keck and the others on the Pennsylvania State Police team, who worked diligently to identify Ruthie. Their work has provided us with some closure on questions that have lingered for the past 51 years." Police are asking anyone who knew her or has information about her to contact the Pennsylvania State Police Jonestown station at 717-865-5067. You can also call the PSP tip line at 1-800-472-8477. The tips can be anonymous. Over the years, investigators tried various methods to identify the person they then referred to as "Jane Doe." In 2015, police released a bust that was recreated based on her remains. But no family members or friends came forward. In 2016, investigators exhumed "Jane Doe's" body. "We already have a DNA profile. So one of the ideas is they're going to do an isotope test," Pennsylvania State Police Trooper David Beohm told sister station WGAL at the time. Investigators hoped that the isotope test might tell them where she lived. "Anything at this point is more than what we have," Beohm said. "We'll do whatever we can to find out who this person is."OTTAWA — Canada's financial intelligence agency says it is modernizing with the aim of providing valuable information to police and security officials in real time — or as close to that goal as it can get. In its newly released annual report, the Financial Transactions and Reports Analysis Centre of Canada says it is working with businesses and federal partners to move more quickly in the fight against money laundering and terrorist financing. The agency, known as Fintrac, identifies money linked to illicit activities by electronically sifting millions of pieces of information each year from banks, insurance companies, money services businesses, real-estate brokers, casinos and others. In turn, it discloses intelligence to police and security agencies about the suspected cases. In 2023-24, Fintrac produced more than 4,600 financial intelligence disclosure packages for recipients including the RCMP, municipal and provincial police, the Canada Border Services Agency and the Canada Revenue Agency. In a message in the report, Fintrac director Sarah Paquet says the agency aims to harness modern skills, tools and technologies to analyze data and produce intelligence in real time. Paquet said such swiftness could be a game-changer, for example, in the agency's efforts to track financial transactions related to human trafficking for sexual exploitation. "It will allow us to proactively identify and assist law enforcement in disrupting networks much quicker," she said. "This will mean rescuing victims sooner, saving them from prolonged abuse. It will mean supporting survivors sooner, getting them the assistance they need in a more timely fashion. And it will help law enforcement target, arrest and charge the traffickers sooner, preventing the abuse of new victims." Fintrac's digital strategy includes advancing automation, analytics and the use of artificial intelligence, Paquet said. In a bid to "stay ahead of the bad actors," Fintrac has created a digital acceleration and modernization team "to experiment with, and exploit, the latest technologies." Transnational organized crime groups and professional money launderers are the most prominent threats to Canada when it comes to illicit cash transactions, the report said. "At the same time, while the threat of terrorist financing is not as pronounced in Canada as it is in other regions of the world, there are networks operating in our country that are suspected of raising, collecting and transmitting funds abroad to various terrorist groups." This report by The Canadian Press was first published Nov. 26, 2024. Jim Bronskill, The Canadian Press
It’s Friday, December 13, and the Los Angeles Clippers (14-11) and the Denver Nuggets (12-10) are all set to square off from Ball Arena in Denver. The Clippers are currently 5-5 on the road with a point differential of 1, while the Nuggets have a 6-4 record in their last ten games at home. We’ve got all the info and analysis you need to know ahead of the game, including the latest info on the how to catch tipoff, odds, recent team performance, player stats, and of course, our predictions, picks & best bets for the game from our modeling tools and staff of experts. Listen to the Rotoworld Basketball Show for the latest fantasy player news, waiver claims, roster advice and more from our experts all season long. Click here or download it wherever you get your podcasts. Game details & how to watch Clippers vs. Nuggets live today Date: Friday, December 13, 2024 Time: 9 pm EST Site: Ball Arena City: Denver, CO Never miss a second of the action and stay up to date with all the latest team stats and player news. Check out our day-by-day NBA schedule page , along with detailed matchup pages that update live in-game with every out. Game odds for Clippers vs. Nuggets The latest odds as of Friday: Odds: LA Clippers (+200), Denver Nuggets (-250) Spread: Nuggets -5.5 Over/Under: 226.5 points That gives the Clippers an implied team point total of 112.22, and the Nuggets 115.61. Want to know which sportsbook is offering the best lines for every game on the NBA calendar? Check out the NBC Sports’ Live Odds tool to get all the latest updated info from DraftKings, FanDuel, BetMGM & more! Expert picks & predictions for Friday’s Clippers vs. Nuggets game NBC Sports Bet Best Bet Drew Dinsick (@whale_capper) grabbed the Clippers and 6.5 points: “The market giving the Nuggets way too much respect here and while the rest may be what they needed to finally find their footing, the Clippers defense is for real and will be a tough test. Fair price is LAC +4.5 by my numbers.” Please bet responsibly. If you or someone you know has a gambling problem, call the National Gambling Helpline at 1-800-522-4700. Our model calculates projections around each moneyline, spread and over/under bet for every game on the NBA calendar based on data points like recent performance, head-to-head player matchups, trends information and projected game totals. Once the model is finished running, we put its projections next to the latest betting lines for the game to arrive at a relative confidence level for each wager. Here are the best bets our model is projecting for today’s Clippers & Nuggets game: Moneyline: NBC Sports Bet is recommending a play on the Denver Nuggets on the Moneyline. Spread: NBC Sports Bet is leaning towards a play ATS on the Denver Nuggets at -6.5. Total: NBC Sports Bet is recommending a play on the UNDER on the Game Total of 226.50. Want even more NBA best bets and predictions from our expert staff & tools? Check out the Expert NBA Predictions page from NBC Sports for money line, spread and over/under picks for every game on today’s calendar! Important stats, trends & insights to know ahead of Clippers vs. Nuggets on Friday The Clippers have won 4 straight games against the Nuggets The Nuggets’ last 3 games have gone OVER the Total The Clippers have covered the spread in 8 of their last 10 games against teams with worse records This has been a favorable match-up for the LA Clippers, who have won four of the last five meetings with the Denver Nuggets and have covered the spread in five of six. The two meetings this season were decided by five and four points, suggesting we’re in for another closely fought clash. If you’re looking for more key trends and stats around the spread, moneyline and total for every single game on the schedule today, check out our NBA Top Trends tool on NBC Sports! Bet the Edge is your source for all things sports betting. Get all of Jay Croucher and Drew Dinsick’s insight weekdays at 6AM ET right here or wherever you get your favorite podcasts. Follow our experts on socials to keep up with all the latest content from the staff: - Jay Croucher (@croucherJD) - Drew Dinsick (@whale_capper) - Vaughn Dalzell (@VmoneySports) - Brad Thomas (@MrBradThomas)
Rivalry Week in the 2024 college football season continued Saturday as the Michigan Wolverines went into Columbus, Ohio, and came out with a huge 13-10 win over Ryan Day and the No. 2 Ohio State Buckeyes. The score was all knotted up at 10 apiece through most of the second half before Michigan stormed down the field and scored a go-ahead field goal with 45 seconds left. An illegal substitution on the Buckeyes with 1:55 remaining became a crucial penalty for Day's squad, as the Wolverines were handed a first down and were able to take more time off the clock before the winning field goal. Since joining the program in 2019, Day has seen his Buckeyes teams rank among the best in the nation. However, he has struggled against Michigan, losing each game to the rival with the exception of Day's first year in Columbus. Overall, Day is 1-4 against the Wolverines. MICHIGAN BEATS NO. 2 OHIO STATE FOR THE FOURTH-STRAIGHT TIME !!️ pic.twitter.com/zW0rVUrZRq Despite having top-tier teams during his six-year tenure with the Buckeyes, Day has also seen his team finish each season with a loss, with the exception of a 2021 Rose Bowl win. With his lack of meeting the program's championship expectations over the past few years, Day has found himself on the hot seat . But, with the latest loss to Michigan, along with some poor decisions down the stretch, demand for his firing has grown even more on social media. "Fire Ryan Day," one fan said . "This team is amazing But the playcalling is what has lost these games. Terrible." "FIRE RYAN DAY," added another with a trash emoji. "Ohio State needs to fire Ryan Day immediately," wrote a third. "Bring back Urban Meyer." "If we do not fire Ryan Day immediately following this game, I’m done," chimed in a fourth. "Ohio State spent $20 million on their roster and couldn't beat an unranked Michigan team at home with a walk-on QB," commented a fifth. "Ohio State has to fire Ryan Day. It's over." "This is the worst moment of my life," added a sixth. "You gotta fire Ryan Day. You can’t lose 4x in a row." © Adam Cairns/Columbus Dispatch / USA TODAY NETWORK via Imagn Images Ohio State (10-2, 7-2 Big 10) is still alive for a spot in the Big Ten Championship Game, but it needs losses by both Penn State and Indiana on Saturday. The Buckeyes could also still make the 12-team College Football Playoff field. However, if Day doesn't lead this team to a title, the program may be making a major decision sooner rather than later. Related: Arch Manning Was The Talk Of College Football On Friday
CHECK OUT: Education is Your Right! Don’t Let Social Norms Hold You Back. Learn Online with LEGIT. Enroll Now! Legit.ng journalist Adekunle Dada has over 7 years of experience covering metro, government policy, and international events Ikeja, Lagos state - A suspected online fraudster, Osang Usie Otukpa, has been arrested for allegedly duping 139 Australians to the tune of $AUD8,000,000 (Eight Million Australian Dollars). The Economic and Financial Crimes Commission (EFCC) operatives arrested Otukpa upon arrival from the United States at the Murtala Mohammed International Airport, Ikeja, Lagos on Friday, December 6, 2024. Otukpa scammed the victims by luring them on social media to invest in his rogue cryptocurrency investment platform, Liquid Asset Group, LAG. PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app! This was disclosed in a statement issued via the EFCC X handle (formerly known as Twitter) @officialEFCC on Friday, December 13. The anti-graft agency said the suspect goes by five aliases, namely: Ford Thompson, Oscar Donald Tyler, Michael Haye, Jose Vitto, and Kristin Davidson EFCC disclosed that the proceeds of the alleged crimes were routed to his bank accounts through a global cryptocurrency exchange platform. Read also Nigerian army explains strategy that made 129,417 terrorists surrender in 6 months The commission said the suspect would be charged to court upon conclusion of investigations. Court Sentences Internet Fraudster to One Year imprisonment Meanwhile, Legit,ng reported that Praise Humphrey Igbo, using the alias Jessica Allen, impersonated a U.S.-based cryptocurrency trader and defrauded Aaron Baker of $115,000 in Bitcoin . The EFCC prosecuted Igbo, leading to his conviction and a one-year prison sentence, with an alternative fine of one million Naira . The court ordered the restitution of recovered assets, including $16,110 in cash and $67,487.79 worth of cryptocurrency, to the victim through the American Embassy. PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy! Source: Legit.ngAntonio Daniels suggests Kristaps Porzingis returning for the Celtics is a cheat code: “He is literally the perfect compliment to finish out that Boston 5”
Welcome to Startups Weekly — your weekly recap of everything you can’t miss from the world of startups. Want it in your inbox every Friday? Sign up here . This week in startup news, we have some contrarian bets, funding rounds from all around the world, new VC funds, and a final word of warning. Most interesting startup stories from the week Several stories this week remind us that just because something didn’t work earlier doesn’t mean it isn’t worth trying from a different angle. Plus, one M&A that gives us a break from other WordPress news. New wave : A new wave of desalination startups is working on deep-sea reverse osmosis , a technology that’s becoming easier to deploy and could bring savings, with projections that it could produce water using 30% to 50% less energy than onshore reverse osmosis. Filling the gap : YC’s latest batch had plenty of AI startups, and some interesting enterprise ones , but the accelerator has reduced its focus on developing markets. In Africa, local accelerators backed by African YC alumni are taking this as an opportunity with new programs. Bett(h)er : WaveForms AI, a new audio large language model (LLM) company, hopes to make AI more personable with its own foundational models. Its founder, Alexis Conneau, is obsessed with the movie “Her,” but also thinking hard about how not to create a dystopia . “We want to do precisely the opposite of what the company in that movie does,” he told TechCrunch. Automatic for the bots : WPAI, a startup that builds AI solutions for WordPress, is getting acquired by Automattic . Its team will lead WordPress’ AI efforts. Most interesting fundraises this week With the end of the year fast approaching, this week brought us many funding rounds, so here’s a sample that also showcases their range, both in size and in geographic distribution. Taking off : Archer Aviation, a startup building vertical takeoff and landing (VTOL) aircraft, raised $430 million in fresh equity funding that brought its total financing to nearly $2 billion. Archer also closed an exclusive partnership with Anduril to jointly build defense aircraft. Stealthy no more : Berlin-based startup Upvest, which makes a stock-trading API used by some of Europe’s biggest fintech companies, raised a €100 million Series C round ($105 million) led by once-secretive VC firm Hedosophia. Robot steps : Swiss robotics company Anybotics, an ETH Zürich spinout building quadruped autonomous inspection robots for industrial applications, raised another $60 million , bringing its Series B round of financing to a total of $110 million. The capital will help it expand in the U.S., where it recently opened an office in San Francisco. Strong credentials : Flare, a Canadian threat exposure management startup, closed a $30 million Series B round of funding led by Base10 Partners . The company wants to help SMBs and mid-market companies thwart the rise of info-stealer malware, or software that collects login credentials, as happened in the Snowflake incident earlier this year. Crossing the Channel : Aqemia, a French startup in the hot AI-enabled drug discovery space, raised its second fundraise of the year: a new $38 million round led by Cathay Innovation, which it will use to hire and open an office in London. Letting VCs in : Numia, a startup from Argentina that brings offline and online customer interaction data into one place, announced a $3.5 million seed round led by Cometa. CEO Gustavo Lauria said the company is already profitable but decided to raise outside capital for the first time to reach customers that are also limited partners in venture funds. Most interesting VC and fund news this week Open to confusion : The OpenAI Startup Fund raised over $44 million for its fifth special purpose vehicle (SPV), which a spokesperson said “will be used to support a variety of existing portfolio companies and to make new investments.” Despite its name, the fund says it doesn’t have OpenAI as an investor but that its backers include Microsoft and other OpenAI partners. New dimension : Dimension Capital raised an oversubscribed $500 million fund to keep on investing at the intersection of tech and life sciences. Portfolio companies include AI biotech companies Chai Discovery and Enveda Biosciences. Paper tiger : Known for the “spray and pray” strategy that led it to invest in over 315 startups in 2021 alone, the 15th fund of hedge fund Tiger performed particularly poorly, with paper losses standing at more than 15% , according to a recent disclosure. Last but not least In an interview, Lead Edge Capital founder and managing partner Mitchell Green told TechCrunch editor-in-chief Connie Loizos that there is “too much money chasing too few companies that are overvalued.” This makes his firm increasingly steer away from typical venture capital deals and toward buyout-like “control deals” more commonly associated with private equity. “I also refuse to invest in companies at 100 times or 200 times or 500 times revenue. That game will end badly,” he predicted.
COLUMBUS, Ohio (AP) — A fight broke out at midfield after Michigan stunned No. 2 Ohio State 13-10 on Saturday as Wolverines players attempted to plant their flag and were met by Buckeyes who confronted them. Police had to use pepper spray to break up the players, who threw punches and shoves in the melee that overshadowed the rivalry game. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Quantum Unveiled: Revolutionizing Finance with Advanced Quantum-Safe Security and AI Compliance on Coinstore
Smart Money Is Betting Big In NOW Options(The Center Square) – Eleven states, led by Texas, have sued the three largest institutional investors in the world for allegedly conspiring to buy coal company stocks to control the market, reduce competition and violate federal and state antitrust laws. The lawsuit was filed in U.S. District Court for the Eastern District of Texas Tyler Division and demands a trial by jury. It names as defendants BlackRock, Inc., State Street Corporation, and Vanguard Group, Inc., which combined manage more than $26 trillion in assets. The companies were sued for “acquiring substantial stockholdings in every significant publicly held coal producer in the United States” in order to gain “power to control the policies of the coal companies,” Texas Attorney General Ken Paxton said. According to the 109-page brief , defendants own 30.43% of Peabody Energy, 34.19% of Arch Resources, 10.85% of NACCO Industries, 28.97% of CONSOL Energy, 29.7% of Alpha Metallurgical Resources, 24.94% of Vistra Energy, 8.3% of Hallador Energy, 31.62% of Warrior Met Coal and 32.87% of Black Hills Corporation. Under the Biden administration, in the past four years, “America’s coal producers have been responding not to the price signals of the free market, but to the commands of Larry Fink, BlackRock’s chairman and CEO, and his fellow asset managers,” the brief states. “As demand for the electricity Americans need to heat their homes and power their businesses has gone up, the supply of the coal used to generate that electricity has been artificially depressed – and the price has skyrocketed. Defendants have reaped the rewards of higher returns, higher fees, and higher profits, while American consumers have paid the price in higher utility bills and higher costs.” Consumer costs went up because the companies “weaponized” their shares to push through a so-called green energy agenda, including reducing coal output by more than half by 2030, the lawsuit alleges. In response, publicly traded coal producers reduced output and energy prices skyrocketed. The companies advanced their policies primarily through two programs, the Climate Action 100 and Net Zero Asset Managers Initiative, signaling “their mutual intent to reduce the output of thermal coal, which predictably increased the cost of electricity for Americans” nationwide, Paxton said. The firms also allegedly deceived thousands of investors “who elected to invest in non-ESG funds to maximize their profits,” Paxton said. “Yet these funds pursued ESG strategies notwithstanding the defendants’ representations to the contrary.” While they allegedly directly restrained competition among the companies whose shares they acquired, “their war on competition has consequences for the entire industry,” the brief states. “Texas will not tolerate the illegal weaponization of the financial industry in service of a destructive, politicized ‘environmental’ agenda. BlackRock, Vanguard, and State Street formed a cartel to rig the coal market, artificially reduce the energy supply, and raise prices,” Paxton said. “Their conspiracy has harmed American energy production and hurt consumers. This is a stunning violation of state and federal law.” The lawsuit alleges the companies’ actions violated the Clayton Act, which prohibits any acquisition of stock where “the effect of such acquisition may be substantially to lessen competition;” and the Sherman Antitrust Act of 1890, 15 U.S.C. § 1 in a conspiracy to restrain trade. It also alleges the companies violated state antitrust laws of Texas, Montana and West Virginia; Blackrock also allegedly violated the Texas Business and Commerce Code by committing “false, deceptive, or misleading acts.” It asks the court to rule that the companies violated the federal and state statutes, provide injunctive and equitable relief and prohibit them from engaging in such acts. It requests that civil fines be paid, including requiring Blackrock to pay $10,000 per violation. Joining Paxton in the lawsuit are the attorneys general of Alabama, Arkansas, Indiana, Iowa, Kansas, Missouri, Montana, Nebraska, West Virginia and Wyoming. The Buzbee Law Firm and Cooper & Kirk are serving as outside counsel. The companies have yet to issue a statement on the lawsuit. The lawsuit follows one filed by 25 states led by Texas against the Biden administration asking the court to halt a federal ESG policy that could negatively impact the retirement savings of 152 million Americans. It also comes after Texas has listed hundreds of companies and publicly traded investment funds, including Blackrock, on its divestment list for advancing ESG and anti-oil and natural gas policies.
AP finds that a Pentagon-funded study on extremism in the military relied on old dataCan you spot all the Taylor Swift references in Lifetime’s ‘Christmas in the Spotlight’?
Wafer Bumping Service Market Analysis By Top Keyplayers - ASE Global, Fujitsu, Amkor Technology, MacDermid Alpha Electronics Solutions, Maxell, JCET Group, Unisem Group, Powertech Technology, SFA Semicon, Semi-Pac Inc, ChipMOS TECHNOLOGIES, NEPES, TI, IntIncumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has Declined by More than 99%, Clinical Strategy has Failed and AIM is on the Brink of Insolvency Act Now to Save AIM Before it is Too Late – The Kellner Group Can Turn AIM Around and Finally Start Creating Value for Stockholders Vote “ FOR ” All Four Kellner Group Nominees for Urgently Needed Change Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Dear AIM Stockholders: Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”), are issuing this open letter to stockholders regarding the 2024 Annual Meeting of Stockholders of AIM ImmunoTech Inc., a Delaware corporation (“AIM” or the “Company”), to solicit your vote to elect each of us to AIM’s Board. We urge you to carefully read our proxy statement and our subsequent communications because they contain important information. Our proxy statement and our other communications are available at https://okapivote.com/AIM/ . Substantial and Immediate Overhaul of the AIM Board is Critical The urgent need for drastic, immediate transformation within the AIM Board is indisputable. Each of the three leading independent proxy advisory firms have acknowledged this in recommending for the election of Mr. Kellner. Two of the three firms acknowledged that the incumbent Board cannot remain in control and recommended for the election of both Mr. Kellner and Mr. Sweeney and against Mr. Equels. 1 Incremental change would be wholly inadequate in this situation. This is not a case of competing visions or differing opinions on AIM’s strategic direction. The incumbent Board has no vision for AIM’s future and no coherent strategy to move the company forward. The scale of value destruction under the incumbent Board’s leadership, combined with their blatant breaches of fiduciary duties (as found by the Delaware Supreme Court), unethical actions, and brazen disregard of stockholders and corporate governance norms, is unprecedented. We urge you to take decisive action by voting on the Gold card for all of the Kellner Group Nominees. The Incumbent Board has Completely Failed and Destroyed Stockholder Value The incumbent Board has controlled AIM for almost nine years since 2016 and failed epically, and dating back even further, Equels (16 years on the Board), Mitchell (26 years on the Board) and Appelrouth (13 years on the Board and consulting) each played a central role in leading AIM down the path of failure and value destruction. 4 When given the opportunity to show they could be responsive to stockholders and fulfill their promise to appoint two new independent directors, the incumbent Board failed yet again. Instead, they appointed Bryan – hand-picked by Equels, without an independent search firm, based solely on a pre-existing relationship with AIM and Equels. This appointment was rubber-stamped by Mitchell and Appelrouth, and Bryan has predictably fallen right in line with their failed leadership. 5 ISS accurately noted that “AIM shareholders did not get an independent voice they were hoping for with Bryan’s appointment.” 6 This is just another example of the incumbent Board’s consistent failure to act in the best interest of stockholders. The following two facts demonstrate beyond question the utter and complete failure of the incumbent Board: AIM’s stock price has declined by over 99% since 2016 when Equels became CEO and Equels, Mitchell and Appelrouth took control of the Board . 7 AIM’s financial condition has deteriorated to the point of functional insolvency, with substantial doubt about its ability to continue as a going concern, insufficient stockholders’ equity to comply with NYSE American listing standards and a lack of viable financing options . 8 The manner in which the incumbent Board brought AIM to this very dire position is even more troubling: They have utterly failed to advance AIM’s clinical program . 9 They have failed to bring a single trial to completion and failed to achieve any FDA approvals. The incumbent Board has consistently neglected to invest in R&D for Company-sponsored clinical trials, and there is no clear strategy or follow-through. Instead, they shift focus aimlessly, chasing fleeting publicity with press releases that are empty of substance, while neglecting to drive trials to completion, secure approvals, or pursue commercialization with any sense of urgency. They delivered zero material process on any of the key clinical indications of Ampligen, failing to advance even a single company-sponsored study to completion. The incumbent Board attempts to hide their failures behind a veil of opacity, but the truth is unmistakable: a stalled program with no direction or visibility or timeline to approvals or revenues. This lack of transparency is, in effect, the only “strategy” the incumbent Board has for its clinical program – and it is failing. They have wasted funds on compensation and unethical litigation to entrench themselves and overseen massive, and increasing, losses . 11 Net losses have totaled over $120 million since 2016 and have accelerated. This is driven by increased G&A, increasing by 2.5x from 2021 to 2023, to support excessive compensation and unethical entrenchment efforts. G&A has been approximately double R&D in recent periods, a totally inappropriate and irresponsible ratio for a clinical stage biotech firm. The incumbent Board, with an average tenure of over 10 years, has not only violated their fiduciary duties but has also shamelessly paid themselves excessive compensation while the stock price has plummeted to less than a quarter. Their failure to act in the best interests of stockholders has directly contributed to the destruction of value, enriching themselves at the expense of AIM’s future. Their corporate governance practices have been abysmal, demonstrating a complete failure of leadership and accountability . 13 These practices include (1) ignoring the will of stockholders by completely disregarding three consecutive failed “say-on-pay” votes, with no meaningful action taken to address the overwhelming disapproval of their compensation practices, (2) making hollow promises to add two new independent directors and review executive compensation, only to betray stockholders by appointing a pre-selected, hand-picked director with deep ties to AIM and Equels, bypassing any independent search process, then engaged the same compensation consultant that had previously recommended excessive pay to conduct a shallow, self-serving review, (3) maintaining a non-stockholder approved poison pill for over 25 years, a blatant disregard for stockholder rights that continues to entrench their control and harm AIM’s long-term value; and (4) launching an aggressive and harmful campaign against stockholders, relentlessly attacking those who seek change and severely damaged the Company financially and strategically and disenfranchised its stockholders. They have violated their fiduciary duties and conducted an egregious self-interested entrenchment campaign that has results in massive waste and destroyed virtually all stockholder value. 16 The Delaware Supreme Court ruled in 2024 that the incumbent Board breached its fiduciary duties. In describing the Board’s adoption of amended bylaws, the court stated that the “ primary purpose was to interfere with Kellner’s nomination notice, reject his nominees, and maintain control ” and that the bylaws were “ product of an improper motive and purpose, which constitutes a breach of the duty of loyalty .” 17 (emphasis added) This illegal behavior by the AIM Board was not an isolated incident. A federal district court in Florida sanctioned AIM and its counsel in 2024 in its Section 13(d) claims against members of the Kellner Group and others – claims that have been dismissed multiple times – for pursuing arguments that were “factually and legally frivolous and advanced for an improper purpose .” 18 The cost of these bad faith actions has been staggering and directly and severely harmed the Company. We estimate the incumbent Board spent between $15 to $20 million in the past two-plus years in pursuit of its self-interested entrenchment campaign . 19 The purpose of this waste was to prevent a meaningful stockholder vote – to deprive stockholders of their basic right to have a say in who represents them on the Board. Now that the incumbent Board has exhausted litigation options to prevent a vote, they have attempted to pad the vote by awarding fully vested shares to executives before the record date, as an advance on future pay – something there is no rational justification for and is a clear continuation of their bad faith and improper purpose. This is shocking and unconscionable behavior – blatantly putting their own self-interest ahead of the Company and its stockholders – to a degree that we have never seen before. The Kellner Group Nominees are the Only Viable Path to Rescue, Rebuild and Revive AIM Collectively, the Kellner Group Nominees will bring a wealth of business, financial, clinical trial, life science and corporate governance experience and much needed credibility to the Board. The incumbent Board does not have the skill set that the Kellner Group does and has no plan to change course . Against all reason, despite overwhelming evidence of their incompetence, and unethical and self-serving actions, they simply ask stockholders to place blind trust in them and their same empty promises that progress is right around the corner. But after nearly nine years of treating AIM like their personal piggy bank, the incumbent Board’s complete and total failure is indisputable. Faced with this harsh reality, they have resorted to attacking us with misleading narratives and outright lies to divert attention from their own disastrous and self-serving record. Here is the undeniable truth: Mr. Kellner and Mr. Deutsch are two of AIM’s largest and long-standing stockholders. We have invested a significant amount in AIM and our sole motivation is to improve performance and create value for all stockholders. We are fully aligned with stockholders and committed to their success . The false narrative being pushed by the incumbent Board – suggesting Mr. Kellner is motivated by personal financial gain to seek reimbursement or will exploit company resources – could not be further from the truth. These claims are completely divorced from reality. Mr. Kellner has spent decades building his business reputation as a trusted investment fiduciary, and this reputation is a testament to his integrity and commitment to the best interests of the investors. All of the Kellner Group Nominees are committed to acting as responsible fiduciaries, focused on financially stabilizing AIM and creating value for all stockholders. This stands in stark contrast to the incumbent Board members, who have egregiously violated their fiduciary duties by prioritizing their own self-interest, resulting in gross waste and destructive value erosion. Similarly, the incumbent Board’s deceitful misrepresentations of settlement discussions is nothing more than bad faith, deliberate attempt to mislead and distort facts. These discussions are a direct result of the incumbent Board’s unlawful entrenchment efforts and involve numerous lawsuits and people unrelated to the Kellner Group. Mr. Kellner remains fully committed to AIM and to using his resources and network to create value if the Kellner Group Nominees are elected . Mr. Kellner and Mr. Sweeney have been transparent about their business relationship – it was disclosed in detail in our proxy statement and Mr. Kellner’s notice. 21 They have long and proven track records of successful investing and running businesses, earning them the trust of their respective investors through exceptional performance and responsible stewardship over many years. Their demonstrated success is a significant strength of our slate and exactly the kind of leadership AIM desperately needs to address its desperate financial situation and secure its successful future. There are absolutely no third parties involved in our efforts that have not been publicly disclosed. None of the participants in our solicitation have any criminal history whatsoever. The incumbent Board’s claims that criminals are involved in the Kellner Group are completely baseless, desperate and outright false . But the incumbent Board needs to look in the mirror – AIM continues to utilize and pay a CRO that was co-founded by a convicted felon, recently convicted of securities fraud related deceiving investors about FDA submissions. This individual was quoted in several AIM press releases in recent years, including promoting clinical progress that did not occur. The parallels are extremely troubling. AIM also resorted to seeking usurious financing from an individual whom the SEC labeled a “recidivist violator of the federal securities laws.” AIM also grossly mischaracterizes Mr. Chioini’s history at Rockwell Medical. Mr. Chioini founded Rockwell and served as CEO for 23 years, and under his leadership became the 2nd largest dialysate supplier in the US with four manufacturing facilities and 330 employees, executed multiple large clinical trials that resulted in multiple FDA approvals, commercialized products, obtained funding through multi-million dollar licensing deals with large pharmaceutical firms and built a business that had a market cap of almost $1.0 billion at its peak. Since Mr. Chioini left Rockwell in 2018, the stock price has declined significantly, losing approximately 95% of its value (Nasdaq: RMTI). AIM also continues to willfully and falsely insist that Mr. Chioini was fired, despite a public record that clearly disproves this claim, including the incumbent Board sitting through a trial that directly dispelled this claim. The truth is that he reached a settlement agreement that resulted in a significant payment to him after a dispute with conflicted board members involving whistleblower retaliation claims made by both him and Rockwell’s former CFO. The incumbent Board’s deliberate misrepresentation of these facts is an outright distortion of the truth, further reflecting their pattern of dishonesty. None of the successes Mr. Chioini achieved at Rockwell have materialized at AIM under the incumbent Board’s leadership, so his proven ability to drive growth, secure FDA approvals, and create value is exactly what AIM urgently needs to turn things around and deliver meaningful results for stockholders. The degree of dishonesty that we have seen from the incumbent Board is staggering . As just one example, they shamelessly attempted to deceive stockholders that the AIM stock price did not decline by over 99% by displaying a 2016 document referencing an unadjusted stock price that did not account for subsequent 1-for-528 reverse stock splits. When we pointed out this blatant misrepresentation, they had the audacity to call us liars. This kind of behavior is not only bizarre, but it shows you can’t believe anything these say – it is like the pot calling the kettle black, and then claiming the sky is not blue. This is their consistent approach – their entire campaign against us revolves around attacking our qualifications, characters, motivations and relationships. But none of it is based in reality whatsoever and it is an intentional, brazen attempt to mislead stockholders and distract from the incumbent Board’s catastrophic failures. The reality is simple: Nothing from the incumbent Board should be trusted . Our Plan will Create Value for Stockholders The Kellner Group is committed to implementing a bold, focused, responsible plan to reverse AIM’s downward trajectory by stabilizing its financial situation, revitalizing its clinical program and restoring real value to stockholders. First and foremost, the Kellner Group will stabilize AIM and ensure it has the financial resources required to continue operations. It is imperative that AIM raise substantial funding in a sustainable way given the catastrophic damage the incumbent Board has inflicted on the Company’s financial health. The Kellner Group Nominees have each successfully raised significant capital, and collectively, have raised over $1.0 billion in investment capital over the years. We have the resources, networks, and credibility to successfully raise the necessary funds and provide the essential runway to finally create value for stockholders and invest in the future of Ampligen. In stark contrast, the incumbent Board simply does not have the credibility, expertise, networks and resources to secure the capital that AIM desperately needs. The incumbent Board’s financing efforts have been disastrous – extremely dilutive and reliant on ATMs, equity lines and excessive warrant coverage. 22 They have failed to secure long-term financing, leaving AIM burdened with massive overhang that has only driven down the stock price. When they have raised capital, they squandered it on self-serving entrenchment efforts, and wasteful G&A and compensation, rather than on meaningful and strategic clinical efforts. 23 The Kellner Group Nominees will draw on their decades of collective experience in generating value for investors, and the trust, credibility and relationships they have built over the years, to attract long-term investment to AIM. We will direct that funding into a sharply focused clinical program. By being transparent with stockholders about AIM’s clinical program and setting clear, achievable goals and timelines, we are confident we can rebuild investor trust of investors and continue to attract capital. The contrast with the incumbent Board could not be more glaring. Once AIM’s financial condition stabilized, the Kellner Group Nominees will take decisive action and implement their plan to revitalize AIM’s clinical program. We will conduct a comprehensive review of the available data on Ampligen, as well as the status of the various ongoing and past trials. This work will begin immediately and will proceed with the urgency it deserves. We will collaborate with AIM’s existing personnel, but will also bring in outside experts in oncology and other relevant fields to ensure AIM’s success. We bring a vast and powerful network of scientific and industry expertise, forged through Mr. Chioini’s extensive career in biotech and pharmaceuticals and Mr. Kellner’s leadership on numerous boards, including the Wisconsin Medical College Board. This network will be instrumental in driving AIM’s turnaround and ensuring its success. Even more compelling, in the past week, we announced the full support of the co-inventor of Ampligen and former CEO of AIM, Dr. Carter, and another former AIM executive, Mr. Springate. Both of these individuals reached out to us due to their deep experience with AIM and Ampligen and their desire to help us deliver the fundamental change AIM so urgently needs. These powerful endorsements underscore the credibility and trust that our team has within the industry and further validates our plan to turn AIM around. This is clear indication that our group has the proven ability to attract the right people, with the right expertise, to collaboratively and effectively work toward turning AIM around and generating meaningful, long-term value for stockholders. The pillars of our clinical program will be as follows: ME/CFS – We will assess whether initiating another Phase 3 trial is viable in the near term, based on the FDA's feedback from 2013. This could potentially accelerate progress and bring us closer to commercialization. Alferon N – We will evaluate the feasibility of restarting production and commercialization of this FDA-approved product, which could generate revenue and strengthen our financial position. Ampligen in Argentina – We will examine whether regulatory and operational efforts can be expedited to launch commercial sales, potentially creating meaningful revenues in the short term. Lastly, but by no means least, we will implement governance reforms and investor outreach that have been completely absent under the incumbent Board. The incumbent Board has not only utterly failed to establish an effective governance structure, but has fostered a toxic, dysfunctional environment marked by unethical conduct, disloyalty to the Company, a constant financial crisis, missed opportunities, and gross mismanagement. Their actions have created a culture of neglect and self-interest that has left AIM in a state of perpetual instability and underperformance. We are committed to making the necessary changes, starting immediately: Board Composition and Independence . We will identify and appoint an additional independent director, with a focus on finding a candidate with no prior history with AIM, with scientific or other relevant expertise, and with a diverse background that reflects a forward-thinking perspective. Compensation Overhaul . We will engage a new, independent compensation consultant to completely restructure AIM’s compensation practices. Our focus will be on slashing guaranteed compensation, reducing executive and director fixed and cash pay, and implementing a performance-driven incentive-based compensation structure with objective performance measures. Poison Pill Review . Review AIM’s poison pill, which has been in effect for almost 25 years without stockholder approval, with consideration of putting it to a stockholder vote if it will be maintained long-term. Investor Communications. Initiate outreach in a transparent manner to stockholders and new investors to tell our story and keep them informed. Unlike the incumbent Board, we will not make empty promises – we will deliver on these critical commitments overhaul the governance structure at AIM to ensure transparency, accountability and long-term stockholder value. The incumbent Board has destroyed stockholder value and imperiled AIM’s future through breaches of its fiduciary duties and bad faith conduct. Stockholders must act now to save AIM before it is too late. We urge stockholders to vote “ FOR ” all four Kellner Group Nominees for urgently needed change. We believe that if the Kellner Group Nominees are elected, AIM’s future will be bright and we stand ready and able to lead a turn around and create value for all stockholders. But if the Kellner Group Nominees do not control the Board, stockholders can expect more of the same value destruction and self-dealing from the incumbent Board and we fear that AIM will have no future at all. Thank you for your support and consideration. The Kellner Group THE KELLNER GROUP URGES ALL STOCKHOLDERS TO VOTE ON THE GOLD PROXY CARD TODAY TO ELECT TED D. KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL SWEENEY If you have any questions, require assistance in voting your GOLD proxy card, or need additional copies of the Kellner Group’s proxy materials, please contact Okapi Partners at the phone numbers or email address listed below. Please also visit https://okapivote.com/AIM/ for additional information. Contact: Okapi Partners LLC 1212 Avenue of the Americas, 17th Floor, New York, New York 10036 Stockholders may call toll-free: (844) 343-2621 Banks and brokers call: (212) 297-0720 Email: info@okapipartners.com Important Information and Participants in the Solicitation The Kellner Group has filed a definitive proxy statement and associated GOLD proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of highly-qualified director nominees at the upcoming annual meeting of stockholders of AIM. Details regarding the Kellner Group nominees are included in its proxy statement. THE KELLNER GROUP STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Information regarding the identity of participants in the Kellner Group’s solicitation, and their direct or indirect interests, by security holdings or otherwise, is set forth in the Kellner Group’s proxy statement and additional proxy materials filed with the SEC. Stockholders can obtain a copy of the proxy statement, and any amendments or supplements thereto and other documents filed by the Kellner Group with the SEC for no charge at the SEC’s website at www.sec.gov . Copies will also be available at no charge at the following website: https://www.okapivote.com/AIM . Investors can also contact Okapi Partners LLC at the telephone number or email address set for the above. _____________________________________________ 1 The third proxy firm, Glass Lewis, did not meet with us. 2 Permission to use quotations from ISS was neither sought nor obtained. 3 Permission to use quotations from Egan-Jones was neither sought nor obtained. 4 See the definitive proxy statement filed by the Kellner Group with the Securities and Exchange Commission (the “SEC”) on November 6, 2024 (the “Proxy Statement”), pg. 17. 5 See the Proxy Statement, pg. 17. 6 Permission to use quotations from ISS was neither sought nor obtained. 7 See the Proxy Statement, pg. 13. 8 See the Condensed Consolidated Balance Sheets included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 14, 2024 (the “2024 Third Quarter 10-Q”). 9 See the Proxy Statement, pg. 16; see also Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 31, 2022; the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023; and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024. 10 Permission to use quotations from ISS was neither sought nor obtained. 11 See the Proxy Statement, pg. 17; see also the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 14, 2024; and the Condensed Consolidated Balance Sheets included in the 2024 Third Quarter 10-Q. 12 Permission to use quotations from ISS was neither sought nor obtained. 13 See the Proxy Statement, pgs. 17-18. 14 Permission to use quotations from ISS was neither sought nor obtained. 15 Permission to use quotations from Egan-Jones was neither sought nor obtained. 16 See Proxy Statement, pgs. 8-11. 17 Emphasis added. 18 Emphasis added. 19 Represents Kellner Group estimate based on increase in Company’s G&A expense from 2021 to 2023 and explanations provided as disclosed in AIM’s Annual Reports on Form 10-K for past two years, together with continued elevated G&A expenses in 2024 to date as disclosed AIM’s most recent Quarterly Report on Form 10-Q. 20 Permission to use quotations from Egan-Jones was neither sought nor obtained. 21 See Proxy Statement, pg. 11 and Schedule 13D/A filed by the Kellner Group on September 11, 2024, Exhibit 99.1. With no basis whatsoever, the incumbent Board has tried to claim that this relationship was not fully disclosed. Once proxy advisory firms began recommending for the election of Mr. Kellner and Mr. Sweeney, the incumbent Board leaned into this allegation that was fabricated out of whole cloth in an attempt to question their characters and deceive stockholders. Rather than honestly explain to stockholders why they believe this successful investing relationship would not be beneficial, which they could have done when it was fully disclosed in detail in the notice months ago, the incumbent Board resorts to craven dishonesty and spins false narratives. It is their modus operandi and they have done it throughout this proxy contest and their self-interested entrenchment campaign. 22 See the Proxy Statement, pgs. 15-16. 23 See the Proxy Statement, pgs. 16-18.Daylight Saving Time To End Soon? Trump Calls It 'Inconvenient And Costly For Nation'
ps888 slot
psn no philippines
yy88888
6 pst to philippine time
bs88 slot